Clinical Trial Update: TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TAK-228 in combination with tamoxifen for ER-positive, HER2-negative breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• TAK-228
• Tamoxifen (tamoxifen)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Estrogen Receptor Positive Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-07-27